Podcasts about mams

In their second project together, writer-directors Alex Garland and Ray Mendoza’s Warfare strikes a much different tone than last year’s Civil War. Garland’s solo writing and directing project, with Mendoza on as a military supervisor, served as a thematic look at the political divide found in the United States— Warfare, despite using similar thematic elements, takes a much more realist filming approach to the war in Iraq. Warfare follows a platoon of Navy SEALs in 2006 Iraq, going through the process of scouting insurgent territory, and eventually finding themselves in a gunfight with people they often identify as MAMs (military-age males). Told using the memories of those involved in this real event, the film isn’t focused on making a political statement on the war itself as much as it is putting together a chain of events that helps viewers understand one story a part of the greater picture of the war in Iraq. The film takes these stories and uses an ensemble cast of up-and-coming actors to help put together a linear story, with D’Pharaoh Woon-A-Tai notably portraying Mendoza, who was one of the Navy SEAL team members involved. Joining us, to discuss their directorial partnership and the work that went into telling this story as truthfully as possible, are Warfare writer-directors Ray Mendoza and Alex Garland.

Bob Deis is a pulp and pop culture historian who collects and writes about vintage men's adventure magazines (MAMs) and paperbacks published in the 1950s, 1960s and 1970s. He owns one of the largest and most complete collections of MAMs in the world.Since 2013, Bob has co-edited the MEN'S ADVENTURE LIBRARY book series with Wyatt Doyle, head of the New Texture indie book publishing imprint. That series, which reprints classic MAM stories and artwork, now includes over 20 illustrated anthologies and art books, including one that focuses on the significant role MAMs played in increasing and shaping public awareness of Bigfoot and other cryptid monsters, titled the CRYPTOZOOLOGY ANTHOLOGY. It features commentary by David Coleman, author of THE BIGFOOT FILMOGRAPHY and was named one of the "Best Cryptozoology Books of the Year” in 2015 by Loren Coleman, founder of the International Cryptozoology Museum.Another recent illustrated anthology co-edited by Bob and Wyatt, ATOMIC WEREWOLVES AND MAN-EATING PLANTS, features supernatural and science fiction stories published in MAMs. It was named as one of the best books in the “Weird Tales' tradition by NEW YORK TIMES book critic Micheal Dirda published in 2023.In 2021, Bob launched MEN'S ADVENTURE QUARTERLY magazine with graphic designer and head of Pulp 2.0 Press, Bill Cunningham. The MAQ reprints MAM stories and artwork, provides background on the writers, artists and magazines, and includes articles about related vintage paperbacks, movies and TV shows. Each issue has a theme.The latest issue, MAQ #11, features classic UFO stories and artwork published in men's adventure magazines in the 1950s, 1960s, and 1970s. Commentary in that issue also shows how MAMs played a key role in increasing public awareness of UFOs and of the U.S. governments' attempts to suppress and coverup reports of UFO sightings. The MAQ has developed a loyal following of fans and for combining classic stories and artwork with the eye-poppingly cool layouts created by Bill. Bob and Bill also co-edit THE ART OF RON LESSER book series, which showcases Lesser's famed paperback cover art, historical artwork and more recent paintings.Bob's main website is www.MensPulpMags.com. He also writes a blog about famous quotations, www.ThisDayinQuotes.com .He lives near Key West, Florida with his beautiful wife BJ (who graciously tolerates his piles of old magazines and books), their three dogs and four cats.The gorgeously illustrated MEN'S ADVENTURE LIBRARY books and MEN'S ADVENTURE QUARTERLY magazine issues co-edited by Bob Deis are available on Amazon worldwide or directly from Bob at:https://www.menspulpmags.com/Bob visits with Talking Weird to chat about an assortment of classic UFO and cryptid cases, first recorded and published in classic men's adventure magazines decades ago, and recently collected and reissued in some of Bob's amazing publications: Including articles from such notable researchers as John Keel, Donald Keyhoe, and Ivan T. Sanderson.Do not miss this fascinating episode about an assortment of some classic as well as some long-forgotten tales of the weird and anomalous.

It's time for another edition of Shauna's School Run! This week, our researcher Shauna visited the lively first-class students at St. Catherine of Siena National School in Kildare. Listen in as these little ones share their heartfelt thoughts on what makes their Mams so special, just in time for Mother's Day. But that's not all! Shauna also quizzed them about scents and perfumes, revealing some hilarious takes on why adults wear them. Hit play now to hear the full episode.

Brian O'Connor of the North Cork Round Table tells PJ that his man creche program is a bit of fun, a bit of badly needed support for men and a bit of time off for the women in their lives! Hosted on Acast. See acast.com/privacy for more information.

Do you have a day for washing your dildo's? Do you use anyone elses sex toys even if its your Mam's? Do you have feelings for your ex even doh your in a relationship? Zena & Danni discuss all this and more in this unhinged episode.

Mams est un entrepreneur, un mentor, un poète, un Parisien. Sa quête de douceur et de simplicité, dans un monde injuste et qui va à 1000 à l'heure ressemble parfois à un parcours du combattant. Alors il porte son armure et met en place des stratégies de rechargement et des bulles d'inspiration en nature, auprès de ses proches, etc.Nous avons parlé du fait de "trop" se remettre en question (l'hyper introspection qui peut rendre fou) et de ce qu'il était possible de mettre en place pour sa santé mentale.Nous avons abordé l'importance du "vivre ensemble" et le fait de faire communauté pour briser la solitude.Un épisode en paix malgré les émotions, enregistré à l'été 2024 en pleine nature.Merci Mams ! Pour le retrouver sur Instagram, c'est par ici.---------------------------------Pour vous abonner au podcast : https://podcast.ausha.co/conversations-au-coeur-des-hommes/ Pour m'aider, et si ce projet vous touche, pensez à laisser des notes 5/5 et des avis sur Spotify et Apple Podcasts ! Merci

Students in Ireland have easy access to a personal “homework genie” powered by artificial intelligence that can do their assignments in a matter of seconds.Teacher Patrick Hickey, an Irish expert in AI and education, says that most teachers, principals and parents are completely unaware that students have access to this level of AI “in their back pocket”...Andrea is joined by Newstalk's Tech Correspondent Jess Kelly, Mary McCarthy, Irish Independent Columnist, Siobhan O'Neill White from Mams.ie and more to discuss.

It's another episode of The Ted Hanky Podcast. Ted and Mala discuss where Ted has been and why the podcast has a new name ... also, Mala has a class idea about offshore Mams at Boro matches! This show is also available for your eyes as well as your lugs ... over on the YouTube channel. Check it out here

▬▬▬▬▬▬▬▬ NEKAO SCHOOL▬▬▬▬▬▬▬▬ Prend ton rendez-vous gratuit, l'un des membres de leur équipe t'aidera et répondra à l'ensemble de tes interrogations. Tu disposeras de 10 % de réduction en passant par le code « KALI » !

People are being encouraged not to buy e-scooters, scramblers, or quad bikes for children this Christmas as Black Friday and Cyber Monday approach due to concerns about safety on roads.What do you think? Should parents avoid buying these types of gifts this Christmas?Andrea is joined by Siobhan O'Neill White, from Mams.ie, Colin Baker, Managing Director of Back from the Future Tech Support and more to discuss.

The boys on the Run Home run their eye through the latest Rugby League news including Ezra Mam, Ronald Volkmann and Ben Hunt's futures 00:00 Ezra Mam seeks medical help 01:00 Statement from Mams management 03:30 Should Ezra have come out in public press conference 08:45 Ben Hunt not expected to talk until have Kangaroos duties 09:15 Where will Ben Hunt play next year 10:50 Eels looking at signing Ronald Volkman Listen to The Run Home with Joel and Fletch live every weekday: 3pm AEDT on SEN 1170 AM Sydney 2pm AEDT on SEN 693 AM Brisbane   Subscribe to The Run Home YouTube Channel https://www.youtube.com/@JoelandFletchSEN   Follow us on Social Media! TikTok:         https://www.tiktok.com/@joelfletchsen Instagram:     https://www.instagram.com/joelfletchsen X:             https://x.com/joelfletchsen Learn more about your ad choices. Visit megaphone.fm/adchoices

A new survey reveals almost 1,000 teaching vacancies nationwide in primary and special schools as principals struggle to fill posts.The survey carried out by the Irish National Teachers' Organisation (INTO), Irish Primary Principals' Network and the Catholic Primary Schools Management Association, says principals have become increasingly reliant on personnel who are not registered with the Teaching Council to cover short-term absences.So, why are primary and special schools across the country struggling to find staff?To discuss, Andrea is joined by Siobhan O'Neill White from Mams.ie, Rachel Harper, Principal of St. Patrick's National School and Padraig Wilson McCarthy, teacher on a career break.

Earlier on Newstalk Breakfast, Dr Richard Hogan, Family Psychotherapist, said that you have to be careful that children understand the value of the money they are getting...When it comes to pocket money, are children losing the value of money? Andrea is joined by listeners, including Siobhan O'Neill white from Mams.ie, to discuss.

Peg Gerrity, MAMS, CMI represents a classic medical illustrator in many ways. Peg has worked for over 30 years as a freelancer, taking on a wide range of projects, many of which were focused on pregnancy and embryonic development. In this episode we talk about Peg's freelance experiences both in US and abroad, her work in traditional and digital media, thoughts on AI and on fundamental business skills. Check out the show notes at: https://www.pkvisualization.com/post/medical-illustration-podcast-peg-gerrity-interview

En el podcast de Rosario Busquets Nosti en Chayo Contigo hablamos sobre:- Diferencia entre un premio y una consecuencia.- ¿Qué pasa con los chats de "mamás" y qué riesgos conlleva?- No te gustó el grupo en el que a tu hijo le tocó, ¿por qué no debes hacer nada?

Columnist with the Irish Independent, Mary McCarthy, was on Newstalk Breakfast this morning chatting about a new movement amongst parents whereby they track their children's locations using their smartphones. So, would you do it? Or are you doing it already?Andrea is joined by Siobhan O'Neill White from Mams.ie, Jen Hogan, Columnist with the Irish Times and mother of seven, Katie Makk from the Opinions Matter Podcast and listeners to discuss.

The lads start off with a special shoutout to those who are into findom as they reckon they'd be raging if they were into it. Kevin also shares details of an absolute ordeal he had at the library that made him wish printers were no longer in existence. The theme for the week is scams and the boys take a look into some of the high profile hustles that have taken place in recent years like Fyre Festival and Anna Delvey. They also talk about things that aren't exactly scams but feel like a scam like Zara sizing and hotel check-out times.Get tickets for the Australian leg of 'That's Showbiz' here: https://linktr.ee/Imgrandmam

An article in the Irish Independent writes:‘The weeks and months after a new baby is born are a vulnerable time for new parents, and while you may not wish to cause offence, well-intentioned, but ill-advised remarks, can land like a lead balloon…‘What are the things you should never say to a new parent?Andrea is joined by Siobhan O'Neill White from Mams.ie and other parents to discuss.

Today's Topics:1. Sound Signature Review 6.156 – KAC 556 QDC/CRS-PRT and 556-QDC/MCQ-PRT System Optimization: SR-15 Carbine MOD 2, CQB MOD 2, M4A1RIII, and MK18 5.56x45mm Short Barrel Automatic AR15 Rifles. Introducing the PEW Science KAC 556 PRT System Optimization Tool!In addition to the first fully-featured public interactive suppressed system optimization tool, this publication includes the following data, analysis, and content for your consumption, including testing with:- Both full size and mini KAC 556 QDC silencers.- Two muzzle devices (3-prong and MAMS).- Four hosts (SR-15 Carbine MOD 2, CQB MOD 2, M4A1RIII, and MK18) – 16 tests, total.This one took a village! Thank you for your support! This is the introduction to this PEW Science Laboratory internal research program publication. (00:09:50)Sponsored by - High End Armament Technology, Top Gun Range Houston, Legion Athletics, and the PEW Science Laboratory!Legion Athletics: use code pewscience for 20% off your first order and double points!Ammo from True Shot: Click Here! (use code pewscience for $20 off the A-Zone program)Magpul: Use code PSTEN to receive $10 off your order of $100 or more at Magpul

During a recent trip away from the family home, Seán's guest realised just how different the roles are that are played by mums and dads. But why is one practical, and the other fun? Joining Séan to discuss is Julie Jay, comedian and Irish Examiner columnist...

During a recent trip away from the family home, Seán's guest realised just how different the roles are that are played by mums and dads. But why is one practical, and the other fun? Joining Séan to discuss is Julie Jay, comedian and Irish Examiner columnist...

This episode we discuss Joels Jibbits/Croc/Cargo shorts drip, Anzac day, War stuff, MAMs, Culture war shit, Excess deaths, Architecture, Tucker on JRE, Intellectual dark web, AI picture generator, Kids being right, Hanging competition and some bread n circus. Enjoy. Support The Joel and Tim Show on Patreon: https://www.patreon.com/user?u=74670148 Support us with caffeinated beverages at https://www.buymeacoffee.com/thejoelandv

People have been divided online after comedian Arj Barker kicked a breastfeeding mother out of a gig in Australia. Was this the right thing to do and do mothers have fair rights to be allowed to go to gigs with their children?Kieran is joined by comedian Jim Elliot and Siobhan O'Neill White from Mams.ie to discuss.

Balandžio 12 d. duris atvėrė restauruoti ir šiuolaikiniam miesto gyvenimui pritaikyti Sapiegų rūmai. Naujieji rūmų šeimininkai – Šiuolaikinio meno centro kolektyvas – pakvietė penkias išskirtines asmenybes (Andrių Arutunian, Renatą Dubinskaitę, Moniką Kalin, Liną Lapelytę, Kristupą Sabolių) sukurti garsinius kūrinius, istorijas, patirtis, kurie ragina tirti ir pažinti Sapiegų rūmų erdves, istoriją, aplinką, su rūmais susijusius žmones.Šiuos garso kūrinius galima susirasti ir išgirsti Sapiegų rūmų internetinėje svetainėje.Pokalbis apie bandymus apmąstyti Sapiegų rūmų kaip atminties vietos reikšmę XXI amžiaus Lietuvos visuomenei, pastangas kurti naują šių rūmų tapatybę ir pastarąją tapatybę išreiškiančias istorijas.Ką daryti su nei atkurta, nei įsivaizduota, nei išgyventa praeitimi? Kaip vyksta vaizduotės dialogas su istorija? Kuomet meninė tiesa tampa svarbesnė už mokslinius teiginius? Kodėl naujiems pasakojimams apie praeitį reikia ne tik iki skausmo pažįstamų didingų naratyvų arkų, bet ir mūsų gebėjimo pastebėti iki šiol nežinomus arba neįvertintus žmones, įvykius, reiškinius?Pokalbis su kuratore Asta Vaičiulyte, menotyrininke ir senosios baroko muzikos atlikėja Renata Dubinskaite, filosofu, scenaristu, rašytoju, prof. Kristupu Saboliumi.Ved. Aurimas Švedas

Two of the biggest podcasters of the moment, Kevin and PJ from I'm Grand Mam caught up with Alison Curtis on Weekend Breakfast. The pair are gearing up for an Irish tour that's sold out half its venues so far, so we found out how they're feeling about it and why their Cork accents seems to be a draw for listeners. Plus, what are the funny things their Mams do? To find out, hit the play button on this page!

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Getting your children to do their homework can be an everyday struggle for many parents. For many children they'll pout and complain so figuring out how to make homework fun can be a tricky task. Kieran was joined by Siobhan O'Neill-White from the parenting website, Mams.ie and TJ Hegarty, Founder of the online maths school, Breakthrough Maths to discuss...

Mams Taylor is the executive producer to KSI, the president of Misfits Boxing and a co-founder of Prime Hydration with KSI & Logan Paul.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Shops like Lidl and Aldi are set to slash their prices over the coming weeks. Aldi said prices had dropped across a range of its products, with the price of a typical trolley set to fall by about a fifth. Lidl will lower the price of 100 products this week, having already reduced the cost of more than 600 since October. Stefanie Preissner was joined by Tim Cullinan IFA President, Damian O'Reilly, a Lecturer in retail management at TU Dublin, Louise Crowley, Full Time Dairy Farmer and Siobhan O'Neill White from Mams.ie to discuss...

Today's Topics:1. Sound Signature Review 6.134 – SilencerCo Velos LBP on the 5.56 MK18. This is the technical discussion for this long-awaited white paper, published last week! Again, big thanks to PEW Science members for making research like this possible. (00:08:53)2. Sometimes it takes a village – KAC silencer system testing is in the works, with contributions from several folks! KAC 556 QDC-CRS/PRT, 556 QDC/MCQ-PRT, and in addition to MK18 and M4A1 midlength 14.5, maybe we do SR-15 Carbine MOD 2 14.5 and SR-15 CQB MOD 2 uppers for members. Oh, and MAMS and 3-Prong. Thanks to several PEW Science Members for making something like this possible. (00:59:51)Sponsored by - High End Armament Technology, Top Gun Range Houston, Legion Athletics, and the PEW Science Laboratory!Legion Athletics: use code pewscience for 20% off your first order and double points!Ammo from True Shot: Click Here! (use code pewscience for $20 off the A-Zone program)Magpul: Use code PSTEN to receive $10 off your order of $100 or more at Magpul

En otro encuentro con el público en Mero Bar, nos pusimos a la tarea de recordar cosas, y más un show de comedia pareció una regresión colectiva.Como siempre, se nos fue el tiempo muy rápido, porque hablar con amigos de temas que nos divierten es tan rico, que uno cuando menos piensa ya han pasado 1 hora y media. Nos dolía la barriga, el cuello, la mandíbula y la cabeza de tanto recordar y reír. Gracias a todos los que creen, aman, ven y escuchan El Método Arjona Project. Por ustedes es que tenemos el mejor "trabajo" del mundo.

Welcome Back Everyone!

Ariel Helwani around (5:34) discusses the new main event at UFC 294, if Alexander Volkanovski is out for the Toronto card, what happened with backup fighter Mateusz Gamrot, the co-main event, and more. In the latest On the Nose around (21:28), Ariel Helwani discusses where it would rank if Alexander Volkanovski pulls off the upset at UFC 294, the UFC's event next year in Saudi Arabia, if Mike Perry knocks out Logan Paul, the skirmishes at Misfits open workouts, and more. Mike Perry around (40:00) discusses crashing Misfits open workouts, his interaction with Anthony Taylor, if he's surprised Dillon Danis is at event, if he would rather fight Jake or Logan Paul, starting his own promotion, his message to Jon Jones, his kids' names, Darren Till, and more. Mams Taylor around (1:57:46) discusses last-minute changes to Misfits card, the chaos with John Fury at Misfits workouts, if he warned Dillon Danis for comments, if it was hard to get Dillon Danis and Logan Paul on the card, KSI vs. Jake Paul, his issues with Nakisa Bidarian, KSI vs. Conor McGregor, the year for Misfits, and more. Tommy Fury around (2:46:39) discusses John Fury's skirmishes at media workouts, if he would end crossover boxing if he beats KSI, KSI's last fight, if he would want to face Logan or Jake Paul next, and more. The parlay pals around (3:03:11) make their pick, and GC makes his selections for the upcoming weekend. If you or someone you know has a gambling problem, crisis counseling and referral services can be accessed by calling 1-800-GAMBLER (1-800-426-2537) (IL/IN/MI/NJ/PA/WV/WY), 1-800-NEXT STEP (AZ), 1-800-522-4700 (CO/NH), 888-789-7777/visit http://ccpg.org/chat (CT), 1-800-BETS OFF (IA), 1-877-770-STOP (7867) (LA), 877-8-HOPENY/text HOPENY (467369) (NY), visit OPGR.org (OR), call/text TN REDLINE 1-800-889-9789 (TN), or 1-888-532-3500 (VA). 21+ (18+ NH/WY). Physically present in AZ/CO/CT/IL/IN/IA/LA/MI/NH/NJ/NY/OR/ PA/TN/VA/WV/WY only. New customers only. Min. $5 deposit required. Eligibility restrictions apply. See http://draftkings.com/sportsbook for details. Learn more about your ad choices. Visit podcastchoices.com/adchoices

"¡Bienvenidos a un nuevo episodio de Transfórmate Mujer Podcast! con Shaida Vázquez

Rechaza AMLO propuesta de Morena de que expresidentes se conviertan en senadoresElementos de la Policía y reos de la cárcel de Tocorón en Venezuela se enfrentanMás información en nuestro podcast

Did you feel comfortable taking maternity leave? Minister for Justice Helen McEntee has said that she is sure 'some people didn't approve' of her taking maternity leave for a second time. Andrea was joined on Lunchtime Live by Clontarf Councillor Catherine Stocker, Dr Niamh Flanagan, Assistant Professor of Social Policy in the Department if Applied Social Studies, Maynooth University, Siobhan O'Neill White founder of Mams.ie and Labour Party South Dublin County Councillor Joanna Tuffy...

Ma, me revisas mi plan de gastos?... será suficiente invertir esta cantidad en el sector inmobiliario o agrego un poco más?... Ya tengo US$1.000 invertidos en la bolsa y están diversificados. Ma, necesito ahorrar US$500 dólares de aquí a setiembre y ya tengo un plan. Esos fueron los agradables comentarios que recibí, justo esta semana, de mis tres hijos de 21, 19 y 13 años. A veces, pensamos que son demasiado chiquitos o inmaduros para aprender de finanzas o están en otro planeta. Pero tus hijos pueden superarte, financieramente, si les enseñas estos principios que te compartiré en este video. Además, quiero enseñarte 3 errores que pueden destruir su vida financiera y de seguro las estás cometiendo.

On todays episode;Jill on the school run, not washing your hair for 28 days, Kyria's sends in a 'Wot you upto', Throuples and dog walks, Mams and Valentines cardsThank you to our lovely sponsorsClubhouse, MeadowhallRedbrik Estate AgentsRingwood Hall hotel and SpaGet in touch with your mate stories;thelauraandbeckyshow@gmail.com We love you! Please become a member here https://plus.acast.com/s/the-laura-becky-show. Hosted on Acast. See acast.com/privacy for more information.

Children in Ireland are waiting up to 13 years to see a dentist. That's the stark warning from the Regional Group of independent TDs. It's bringing a motion before the Dáil later today, calling for the government to immediately reform the public dental system. Have you experienced delays in getting a dental appointment? Andrea was joined by Fintan Hourihan, Chief Executive of the Irish Dental Association, Dr Bernie Fee, Fee Dental Carrickmacross, Siobhan O'Neill White, Founder of Mams.ie and other listeners to discuss…

El sentimiento de que la vida como la conocíamos termina cuando tenemos hijos es válido. Porque es cierto!! Tu vida no volverá a ser la de antes. Será una nueva vida, con muchísimas alegrías y aprendizajes. Y te alegrará saber que en esa nueva vida, podrás proponerte grandes cambios. Danié lo ha hecho, y aquí nos cuenta cómo la maternidad no es todo lo que la define, y cómo trenza esos "hilos invisibles" que marcan su vida y la de sus hijos.

Academics in California have warned new mothers against the over-use of online parenting forums. This follows research that found that mothers who regularly logged on to parenting websites were more stressed as a result of comparing themselves to others. Andrea was joined by Siobhan O'Neill White from Mams.ie and other mothers to discuss...

Welcome to our School Spotlight Series! In this series, we will be dropping episodes dedicated to sharing the good works, special programs, and unique culture wins that are happening all around the country so you can take them back to your school community! This week we are joined by Kanetha Callahan, who is the Community Achieves Site Coordinator for Margaret Allen Middle School in Nashville, Tennessee. Kanetha shared the great ways they are supporting international students, building community partnerships, and how they are aligning MAMS's behavior expectations with the 7 Habits of Highly Effective People using LiveSchool. Links: You can find MAMS on Instagram and on Twitter. Or you can reach out to Kanetha by email at Kanetha.Callahan@mnps.org And don't forget to check out MAMS Behavior Rubric by heading over to our Instagram! We have a mailbag episode coming up and we want to feature your questions! Leave us a question by clicking here! Or you can subscribe to the LiveSchool Leader by clicking here! Want to see our smiling faces? Subscribe to our Youtube Channel Or Follow us on Instagram: @getliveschool Or TikTok: @whyliveschool for incredible resources on School Culture check us out at www.whyliveschool.com

Mamula “Mams” Notes   Mam - you - la    Bio HC at University of Delaware First year as HC Former recruiting coordinator and associate head coach at Florida Atlantic University3 NCAA Regional appearances and won 2 Conference USA regular season titles 2019 Conference USA Assistant Coach of the Year  Former assistant coach at the University of Cincinnati  Former head coach at West Chester University for three yearsPSAC East Coach of the Year and Atlantic Region Coach of the Year in 2009 Reached the World Series and placed 7th Former assistant coach and recruiting coordinator at Delaware from 2002-06  mamula@udel.edu Notes Change the expectations Everything worthwhile is uphill! We will resort to what we know Its the guys that genuinely care about each other are the teams that win in April and May Getting to know each other the last 10 minutes of practiceHero, highlight, hardship NO CAPTAINS Leadership training - 21 laws of leadership - each guy teaches 1 law of leadership and how to apply it to the program Last 10 minutes of weight room break it down and call out players who did it well that day! We are all leaders! Household, job,  Only as effective as the guys handle it and deal with it Not having captains because we are all leaders and can lead in different ways It is important to the staff that the players feel it is their team!! Naming guys captains put undo pressure on them I'm going to take notes and discuss/evaluate the next day  Nobody is going to hit more on the field as much RotationsCoach BP (3 days) Machine BP (2 (days) Everyday rounds they don't know what is coming Scripted and know the goal each round Recycling the good rounds Records are posted!! Chart all Bp (hard hit or not) Rank the hard hit % of hitters each day If you are going to spaz out in BP we got no shot in the game Defense is about getting pre pitch and first step down, we know you can catch the ball I want them to practice to get to that swing if they are a power guy Total rounds - 6 swings. Lose swings when don't get bunt down Get some bunts down to help not shift Break the plate into thirds We fall back to our training, if we trained appropriately then we just compete Avoid talking about striking out!! We want to be fearless and not worrying about striking out 2K approachEvery swing is aggressive In the end we still want to hit doubles and hit the ball hard At our level we don't just put it in play Fear not getting off aggressive swings!! Personal 2k adjustments - in the box, hands, swing, etc Leave them be and see what works for them Early Work - Warm up with tee, flips, and most work with coach throwing over hand or off machine BP is hard in our program We will mix in feel good BP as needed Major leaguers can practice at 50%, but the lower levels just cannot practice at that level. We need to do practice different  

New research from the ERSI has revealed that more than half of nine-year-old's now own a phone. Kieran was joined by Siobhán O'Neill White, founder of Mams.ie and Karl Hegarty, Principal of Leinster Senior College to discuss...

The issues of keeping children on the sideline has cropped up again today, it comes off the back of a piece by contributor to this show, Jen Hogan in the Irish Times today, where she spoke to parents of kids being kept on the sideline. Kieran was joined by Shane Coleman, Newstalk Breakfast presenter and Siobhán O'Neill-White from Mams.ie to discuss...

This week Sanjay is joined by Lisa Parkins, Lisa is a journalist and YouTube vlogger also known as Teddy Has Two Mams, she can also be found posting pictures of messy kids on Instagram.  Her words not mine!  We chat about her life as parent to two young children, dealing with awkward conversations and coming out as a parent, the different reaction gay dads get vs gay mums, talking to children about Pride and how to ensure they have diverse role models and representation in their lives.The Proud Parent Club is the inclusive LGBTQ+ parenting podcast and community hosted by Sanjay Sood-Smith, gay dad through surrogacy with his husband Doug, a.k.a. The Travelling Gays.  Subscribe for reminders of each LGBT parenting podcast out weekly and follow us on Instagram.  Whether you are an LGBT parent or lesbian, gay, bi or trans future parent there will be something for you. Teddy Has Two Mams: @teddyhastwomams | www.instagram.com/teddyhastwomams  The Travelling Gays: @thetravellinggays | www.instagram.com/thetravellinggays  The Proud Parent Club: @theproudparentclub | www.instagram.com/theproudparentclub | www.theproudparentclub.com lgbt parent, lgbtq parent, lgbtq, lbgtq parenting, lgbt parenting, parenting, ivf, adoption, surrogacy, lesbian, gay, bi, trans, parents, lgbt family

On Episode 16 of the Stroke Alert Podcast, Dr. Negar Asdaghi highlights two articles from the May issue of Stroke: “Number of Affected Relatives, Age, Smoking, and Hypertension Prediction Score for Intracranial Aneurysms in Persons With a Family History for Subarachnoid Hemorrhage” and “Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia.” She also interviews Dr. Patrick Lyden on “The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.” Dr. Negar Asdaghi:         Let's start with some questions. 1) How is it that stroke can be cured in rodents but not in humans? 2) Are we wasting time or gaining time with general anesthesia before endovascular thrombectomy? 3) My father had an aneurysmal subarachnoid hemorrhage, Doctor. What is my risk of having an aneurysm, and how often should we check for one? We're back here with the Stroke Alert Podcast to tackle the toughest questions in the field because this is the best in Stroke. Stay with us. Dr. Negar Asdaghi:         Welcome back to the May 2022 issue of the Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. For the May 2022 issue of Stroke, we have a number of papers that I'd like to highlight. We have seven articles as part of our Focused Update on the topic of neuroimmunology and stroke, organized by our own Stroke editors, Drs. Johannes Boltze and Miguel Perez-Pinzon. We also have an interesting study by Dr. David Saadoun and colleagues from Sorbonne University in Paris, where we learn that in patients with Takayasu disease, how the delay in diagnosis, as defined by the time from symptom onset to the diagnosis being over one year, was significantly associated with development of ischemic cerebrovascular events. In the Comments and Opinions section, we have an interesting study by Dr. Goldenberg and colleagues from University of Toronto on the benefits of GLP-1 receptor agonists for stroke reduction in type 2 diabetes and why should stroke neurologists be familiar with this new class of diabetic medication. Dr. Negar Asdaghi:         Later, in the interview section of the podcast, I have the great honor of interviewing Dr. Patrick Lyden, one of the founding fathers of thrombolytic therapy in stroke, as he walks us through the Stroke Preclinical Assessment Network and what his hopes are for the future of stroke therapy. I also ask him for some advice, and he did tell us about the view from the top, as he truly stands on the shoulder of giants. But first with these two articles. Dr. Negar Asdaghi:         In a landmark population-based study out of Sweden that was published in Brain in 2008, we learned that the odds of development of aneurysmal subarachnoid hemorrhage for individuals with one first-degree relative with a prior history of aneurysmal subarachnoid hemorrhage was 2.15. For individuals with two affected first-degree relatives, the odds ratio was 51. So, it's not surprising that a great deal of anxiety is caused within a family when a relative has an aneurysmal subarachnoid hemorrhage, especially if that family member was young or another member of the family had the same condition before. This scenario is commonly followed by a number of inevitable questions: Should all family members of the affected individual be screened for presence of an intracranial aneurysm? If yes, how often should vascular imaging be performed, and should other aneurysmal risk factors, such as age, sex, smoking, and hypertension, be also considered in the screening decision-making? In this issue of the journal, as part of a derivation-validation study, a group of investigators, led by Dr. Charlotte Zuurbier from University Medical Center at Utrecht Brain Center in the Netherlands, studied the ability of a simple scoring system that was developed in their derivation cohort to predict the presence of an intracranial aneurysm on vascular imaging. Dr. Negar Asdaghi:         They then tested the scoring model in their validation cohort. So, for their development cohort, they used data on 660 persons who were screened at the University Medical Center for presence of an intracranial aneurysm because they had two or more affected first-degree relatives with a prior history of aneurysmal subarachnoid hemorrhage. The median age of participants at the time of first screening was 40, and 59% were female. Dr. Negar Asdaghi:         So, in this cohort, the investigators simply looked at factors that were independently associated with finding an aneurysm on vascular screening by their multivariate analysis. And they identified the following factors; the first factor was the number of affected relatives. Now, a reminder that all of these people in the cohort had at least two first-degree relatives with an aneurysmal subarachnoid hemorrhage. And they found that amongst these people, those that had three or more family members with aneurysmal subarachnoid hemorrhage were significantly more likely to have a positive screening test for intracranial aneurysm. The next factor was older age — the older that relative, the more likely their screening imaging was positive for an aneurysm — and the other independent factors were smoking and hypertension. So they created the NASH acronym; N for number of relatives, A for age, S for smoking, and H for hypertension. When assigning points for each of these factors, the NASH scoring system had a C statistics of 0.68 in predicting whether or not someone would have a positive test, which is an intracranial aneurysm. Dr. Negar Asdaghi:         And now a reminder for our listeners that C statistics gives us the probability that a person with a certain condition, in this case, a certain NASH score, will have the outcome of interest, in this case, an aneurysm found by vascular imaging. In general, for C statistics, the closer we get to 1, the more robust is our predictive model. Values over 0.7 indicate that we have a good model, but values over 0.8 indicate a very strong model. So the NASH score, at 0.68, has a reasonably good capability in predicting who will or will not have an intracranial aneurysm if we complete the vascular imaging. But it's not a very strong model, and this should be kept in mind. Let's look at some of their numbers. In their development cohort, the probability of finding an intracranial aneurysm for a person who scored low on NASH, that is a young person who never smoked and is not hypertensive, was only 5%, whereas the probability of finding an intracranial aneurysm in a person who scored high on NASH, that is an older person in their 60s or 70s, with three or more affected relatives, who is hypertensive and a smoker, was 36%. Dr. Negar Asdaghi:         So, then they tested this NASH score in their external validation cohort and found that the likelihood of identifying an aneurysm increased as expected along the range of predicted probabilities of NASH. That is, the higher the score, the more likely to find an aneurysm on screening with vascular imaging. And the C statistics in the validation cohort was slightly lower than the C statistics in the derivation cohort. So, the important lesson we learned from this study is that the risk of having an intracranial aneurysm in a person who has a first-degree family member with a prior history of aneurysmal subarachnoid hemorrhage is substantially different depending on their NASH score, and this should be taken into consideration when deciding on screening and counseling various family members of the affected patient or prioritizing who should be screened first in routine practice. Dr. Negar Asdaghi:         The ideal anesthetic management during endovascular therapy is still unknown. A number of studies have compared the different anesthetic options available during thrombectomy, which include general anesthesia, or GA, conscious sedation, use of local anesthesia, and no sedation at all. The main argument for doing endovascular therapy under general anesthesia is that although this procedure will take some precious pre-thrombectomy time, it does result in strict immobility. And that is really ideal in the sense that it improves catheter navigation and interpretation of angiography, in addition to obviously providing a secure airway and, of course, avoiding the need to have to do an emergency intubation in case of procedural complications. The argument against general anesthesia is not only the issue of time but also the risk of hypotension and hemodynamic compromise, especially during induction, and the loss of very valuable neurological examination in a completely sedated patient during the procedure. Dr. Negar Asdaghi:         The question is, does general anesthesia improve or worsen neurological and functional outcomes post-thrombectomy? Several smaller randomized trials have looked at this very question, mainly comparing GA to all other forms of sedation during thrombectomy, but they have yielded inconsistent findings regarding the three-month functional outcome. Dr. Negar Asdaghi:         Some of them showed that patients under GA ended up doing better. Some showed no difference in the overall outcomes. But overall, their pooled analysis suggested that GA might be superior to the competing counterpart, which is the conscious sedation, and associated with better functional outcome. But these centers had highly specialized anesthesia teams, and it's possible that their findings may not be generalizable to routine practice. So, in this issue of the journal, using the Swiss Stroke Registry, Dr. Benjamin Wagner from the Department of Neurology at the University Hospital in Basel and colleagues report on the outcomes of endovascularly treated patients in the Swiss Stroke Registry receiving thrombectomy for an anterior circulation stroke with or without general anesthesia. The primary outcome was disability on the modified Rankin Scale after three months. For this study, they excluded one out of the nine centers in the registry that had lots of missing data on their three-month follow-up. Dr. Negar Asdaghi:         And so, from 2014 to 2017, 1,284 patients across eight stroke centers in the registry were included in this study. Sixty-six percent received thrombectomy under general anesthesia. On baseline comparison, the patients in the GA group were older, had a higher NIH Stroke Scale on admission, had worse preclinical functional status, and more likely to have presented with multi-territorial ischemic stroke. So, many reasons as to why people who underwent general anesthesia would have a worse clinical outcome in this study. So, now let's look at their primary outcome. In the unadjusted model, the three-month modified Rankin Scale was significantly worse in the GA group as compared to the non-GA group, which is obviously expected given the differences in their baseline characteristics. Dr. Negar Asdaghi:         But what was surprising was that the odds of having a higher mRS score was significantly greater still in the adjusted models. They also did propensity score matching analysis, and they found that the NIH Stroke Scale after 24 hours, and the odds of dependency and death and mortality were all higher in the adjusted model in the GA group. They also looked at a number of secondary outcomes and found that door-to-puncture time was longer in the GA group. Dr. Negar Asdaghi:         And also these patients were more likely to be transferred to ICU after treatment as compared to the non-GA treated counterparts. The authors point out that these real-world data are in keeping with the findings from the HERMES meta-analysis, which included over 1,700 endovascularly treated patients, and two previously published large registry data, one from Italy, which included over 4,000 endovascularly treated patients, and one from Germany, including 5,808 patients, all of them showing a worse functional outcome in endovascular therapy if the treatment was performed under general anesthesia, as compared to all other forms of sedation or no sedation at all. Again, these findings are in contrast with the reassuring results of the randomized trials on this topic, specifically in contrast to the AnStroke, SIESTA, and GOLIATH randomized trials, which compare GA to conscious sedation, showing either neutral or positive results in favor of general anesthesia pre-thrombectomy. Dr. Negar Asdaghi:         So, in summary, what we learned from this real-world, observational study is that general anesthesia was associated with worse functional outcome post-endovascular thrombectomy, independent of other confounders, which means that the jury is still out on the ideal form of anesthesia for an individual patient prior to endovascular therapy, and we definitely need larger, multicenter studies on this topic. Dr. Negar Asdaghi:         There are over a thousand experimental treatments that have shown benefit in prevention of neurological disability in animal models of ischemic stroke but have failed to show the same efficacy in human randomized trials. In fact, to date, reperfusion therapies, either in the form of intravenous lytic therapies or endovascular treatments, are the only successful treatments available to improve clinical outcomes in patients who suffer from ischemic stroke, and stroke remains a leading cause of death and disability worldwide. How come stroke can be cured in rodents but not in humans? Are neuroprotective therapies, or as more correctly referred to, the cerebroprotective therapies, the epitome of bench-to-bedside translational research failure? And if this is true, what are the key contributors to the scientific conundrum, and how can this be averted in the future? This is the question that a remarkable group of neuroscientists, led by Dr. Patrick Lyden from University of Southern California, are hoping to answer. Dr. Negar Asdaghi:         In this issue of the journal, these investigators describe the rationale, design, feasibility, and stage 1 results of their multicenter SPAN collaboration, which stands for the Stroke Preclinical Assessment Network. I'm joined today by Professor Lyden himself to discuss this collaboration. Now, Professor Lyden absolutely needs no introduction to our stroke community, but as always, introductions are nice. So, here we go. Dr. Lyden is a Professor of Physiology, Neuroscience, and Neurology at Zilkha Neurogenetic Institute, Keck School of Medicine, at USC. He has truly been a leader in the field of preclinical and clinical vascular research with over 30 years of experience in conducting studies and randomized trials, including conducting the pivotal NINDS clinical trial that led to the approval of the first treatment for acute ischemic stroke in 1996. Throughout his exemplary career, he has accumulated many accolades and is the recipient of multiple awards and honors, including the prestigious 2019 American Stroke Association William Feinberg Award for Excellence in Clinical Stroke. Good morning, Pat, it's truly an honor to welcome you to our podcast today. Dr. Patrick Lyden:            Thanks, I'm glad to be here. Dr. Negar Asdaghi:         Well, in the era of successful reperfusion therapies, it seems that the new generation of stroke neurologists and interventionalists have their eyes, so to speak, on the clock and are interested in opening the blood vessels and opening them fast. In the age of reperfusion treatments, why do we still need to talk about the role of cerebroprotective treatments? Dr. Patrick Lyden:            Well, not to sound too glib about it, but not everybody gets better after a thrombectomy. So, thrombectomy is good, it's more effective than anything else that we've tried before, but there are a remaining number of patients with a residual disability. Not only that, and from a more scientific standpoint, thrombectomy offers us the opportunity now to combine cerebroprotective therapy with known reperfusion. Remember, before, we didn't know when the artery had opened, but now we do an embolectomy, we know there's reperfusion. It gives us the opportunity to know that we're combining our treatment with reperfusion. Dr. Negar Asdaghi:         So, in the paper, you discussed how hundreds of treatments have been studied and shown efficacy in reducing neurological disability in animal models of stroke, and yet failed in human studies. In your opinion, what were the top two most disappointing studies in terms of clinical failure despite pre-clinical encouraging data? Dr. Patrick Lyden:            Well, the first one I mentioned was personal because it was the first one that I led, and it was a molecule called clomethiazole that I had helped establish the rationale for in my very first grant. So, it was the first trial I led, it was multinational, and, of course, I firmly believed we were going to hit a home run, and we failed. But to the field, the real watershed moment in neuroprotective therapy was the so-called SAINT II Trial. SAINT II was a study of a drug called NXY-059, and it was the first drug that purportedly had satisfied all of the so-called STAIR criteria. The STAIR criteria came out of a roundtable between academics and industry on how to best qualify drugs preclinically before going to human trials. And the idea was, if you were a 10 out of 10 on the STAIR criteria, then you should win when you come to human clinical trials. And the SAINT II Trial, which I was a co-leader, a co-investigator, on, also failed. Dr. Patrick Lyden:            And so many, many, many drugs had failed by that point. Tens of millions, if not a hundred million dollars, had been spent by industry, and SAINT II really caused the field to stop. Industry stopped investing in stroke; academic investment in stroke dried up. NIH funding became more difficult to get after SAINT II, and that really was sort of the really historical low moment in the development of treatment for stroke. Dr. Negar Asdaghi:         I was a resident when SAINT II came out, and I remember that somber feeling. Dr. Patrick Lyden:            It was a sad day. Dr. Negar Asdaghi:         Yeah. So, in the paper, you outline a number of potential causes as to why this translational failure may have occurred. But you highlighted the absence of preclinical scientific rigor as the most responsible source. And you already alluded to this a little bit. Can you please tell us a bit more? Dr. Patrick Lyden:            Absolutely. And first, of course, we have to say that the ideal clinical trial design is not available. We really don't know the absolute best way to test the drugs in human clinical trials. But leave that for another day. Dr. Patrick Lyden:            On the preclinical side, what can we say we're doing wrong? We're not sure, but one thing that has been highlighted over and over is that we don't approach preclinical characterization with as much rigor as we should. What do I mean by that? Animal models recapitulate for us some of the biology of a stroke, but not all. For example, many, many times we test a drug in a young model, an animal that's quite young, corresponding to a late teenager in human terms. Well, that's ridiculous. Stroke occurs in elderly people, and so on. So, the NIH called in a landmark conference for additional rigor, enhanced rigor. And I should mention the STAIR criteria were a first attempt at this. STAIR put out guidelines that said animals should be elderly, the animals should be randomized, et cetera, et cetera. And so that didn't happen. Although the STAIR criteria were out there, very few laboratories really committed to full rigor. And so the NIH funded the Stroke Preclinical Assessment Network, SPAN, to implement every aspect that we could think of that would add the best possible scientific design, the utmost rigor. So, we implemented true blinded assessment, true randomization, complete case ascertainment where we follow every single subject in the study and account for dropouts and subjects that don't complete the treatment, and, most importantly, a proper statistical design with adequate power and very large numbers. And the hypothesis that we're testing is that additional rigor in SPAN will lead to a better positive predictive value when we think about drugs that should go forward for testing in human stroke trials. Dr. Negar Asdaghi:         So, I think you already answered my next question, which was basically, why do you think SPAN is going to achieve what all others have failed to achieve? But I wanted to simplify and repeat what you mentioned. So, in simple terms, what SPAN is trying to do is to bring all preclinical research to a level of scientific rigor that was not necessarily present and make it a multicenter effort. And can you a little bit tell us about the different stages, again, of SPAN? Dr. Patrick Lyden:            Well, I'm not arguing that all preclinical research needs to be done following a SPAN type of model. Where SPAN fits in is at the end of a development project. So, if you want to characterize the cellular and molecular mechanisms, you don't need to do all of this rigor that we're doing. Just study the drug in the lab and do the mechanistic studies that need to be done. If you want to do dose finding, it doesn't need to be done this way. But at the end of that, OK, first we establish the mechanism, that's the first stage. Then we establish the toxicity. Then we establish target engagement. At the end, we are looking for some evidence that the drug will have a beneficial effect on outcomes. And in previous animal models, the only outcome, generally, the most common outcome that was studied, was size of the stroke. But in humans, the FDA does not recognize stroke size as a valid outcome. Dr. Patrick Lyden:            We look at function, most often measured with the Rankin score and the NIH Stroke Scale. So, we had to create a functional outcome, and then we had to study it at multiple laboratories to make sure we could replicate the effect across multiple sites. And we chose what's called a multi-arm, multi-stage (MAMS) statistical design. All the drugs start out in the experiment at the end of the first interim analysis, which is 25% of the sample size. We cull any compounds or treatments that appear futile are removed. Any that appear effective move on. At the end of the second stage, there's more culling. There's a total of four stages, and we're about to enter stage four, by the way. That's starting next week. And in stage four, there will be, at most, two, maybe only one treatment that has appeared non-futile and possibly effective for final characterization. Dr. Negar Asdaghi:         So, really interesting. I just want to highlight two important comments that you mentioned for our listeners again. So this is multi-layer, as you mentioned, multi-arm, multi-stages. It's sort of filter by filter, just ensuring that what we're seeing, the efficacy we're seeing in preclinical studies, will potentially be replicated in clinical studies. And what you mentioned that's very important is outcomes that classically is measured in animal models are infarct volume that are obviously very important but not necessarily may translate to exactly what we look at in clinical studies, which is functional outcomes, modified Rankin score and NIH Stroke Scale. So, with that, I want to then come back to the treatments that are actually being studied as part of SPAN. You have six very different agents as part of SPAN, from tocilizumab to uric acid. Why do you think these therapies will work? Dr. Patrick Lyden:            Well, my job as the PI of the coordinating center is to remain completely agnostic to the treatments. So, everybody's equal, and they all come in on an equal playing field. We actually have a mechanical treatment called remote ischemic conditioning, as well, and then five drugs. And these were selected through a peer review process at NIH. And then we were informed at the coordinating center what drugs we would be studying. Five drugs and one treatment. And then, of course, the challenge to us was to somehow create a blinded, randomized situation. Now, this turned out to be a fascinating, it's more mechanical, but how do you blind when some of the drugs are given orally, some are given intraperitoneally, some are given intravenously, some are given once, some are given multiple times? So, we had to work with the manufacturers and inventors of these drugs and figure out a way to package them, and in the paper, actually, there's a photograph in the appendix that shows we had to find these bottles that were amber-colored and how to load them and lyophilize the drug. Dr. Patrick Lyden:            And it's actually pretty fascinating how we were able to get all of these different, wildly different therapies, as you say, into a paradigm where they could be tested one against another in a truly blinded, truly randomized way. Dr. Negar Asdaghi:         Do you think you can go on record and say which one is your favorite? Dr. Patrick Lyden:            My favorite drug's not even in SPAN. I am truly agnostic because where my heart is, is with a drug that I've been studying in my laboratory completely separately and not part of SPAN. Dr. Negar Asdaghi:         All right, so we don't have a favorite. So, in a recent review article in Stroke, you commented on treatments used by ancient Persians, Greeks, and Romans to remedy the brain affected by stroke and how the future generation of physicians will look back at our current practices of stroke with the same, how you said, awe and bemusement we hold for Galen, Aristotle, and Avicenna. How do you think stroke will be treated in the year 2222? Dr. Patrick Lyden:            Well, first of all, and to be serious for just one moment, 200 years from now, I worry more about the climate than about medicine. And I really believe our biggest efforts need to be spent on saving the planet. But assuming we make it that long, obviously diagnostic methods will be completely different. Using ionizing radiation to scan the body will be laughed at by physicians in the future. There'll be detection technologies that aren't even on our radar yet today. And then treatments will be cellular focused and regionally focused. We give a drug through a vein and it circulates throughout the entire body, and I'm sure physicians in the future will find a way to somehow get treatment into the part of the body that's injured, not the whole body. And then, who knows? All we can say is they will laugh at us in the same way that we laugh at Theodoric the Barber of York. Dr. Negar Asdaghi:         Let's move on from the future to the past. You're arguably one of the founding fathers of reperfusion therapies. You were instrumental in getting intravenous lytic therapy approved in 1996. It literally took the field 20 years for the next treatment to be approved, that's endovascular treatment. If you could go back in time and give your young self an advice on the subject of research, of course, design and execution, what advice would you give yourself? Dr. Patrick Lyden:            Don't listen to old guys. We got a lot of advice from gray-bearded folks back when we were putting together the tPA trial, and fortunately we ignored some very bad advice and did what we imagined was the right thing to do as young, headstrong up-and-comers do. The other thing is, we really believed that by publishing our science very objectively, without editorial comment, we would be listened to. And that was dead wrong. So, the data was printed in the New England Journal in a very neutral tone, and we felt people would read that data and they would start using tPA the day after the publication. And, as you say, it took 20 years for tPA to really gain widespread acceptance, thrombolytic therapy. Today, people view it as standard, but it wasn't that way at the beginning. And I would say to myself and my colleagues at that time, "Don't be afraid to promote a positive result." Yes, it has to be done with the utmost rigor, but once you have a positive result, there will be plenty of people around pretending they know more than you and telling the world why you are wrong. And it's very important to stand up for your science and stand up for your results and say, no, no, no, no, that interpretation is wrong. The data says what we said it says, and this is an effective treatment and should be used, as an example. Dr. Negar Asdaghi:         What a great advice. Just be bold and say it loud and stand up for your science. Pat, it's been a pleasure interviewing you and having you on the podcast. We really look forward to watching your research. Bring, let me say it again, 2222 closer to now. Dr. Patrick Lyden:            Thank you. Glad to be here. Dr. Negar Asdaghi:         Thank you. Dr. Negar Asdaghi:         And this concludes our podcast for the May 2022 issue of Stroke. Please be sure to check out this month's table of contents for the full list of publications, including two articles on quality improvement in stroke and neurohospitalist—inpatient teleneurology, which comes as part of our Advances in Stroke series prepared by our section editors. And as we close our podcast today, let's take a moment and ask ourselves the same question that I asked Dr. Lyden earlier. What is the next frontier in stroke treatment? Past reperfusion therapies, we have to find ways to preserve the neurons and not just the neurons, all components of the brain. So, is the future of stroke therapy cerebroprotection? Ever since the dawn of history, humanity has lived alongside of death with the conscious apprehension that as we age, we lose the very gift of life. But unlike our ancestors, the search for immortality isn't the quest to find a fountain of youth anymore. We learned that death is inevitable, but with medicine, we can reduce illness and suffering to prolong a life worth living, one with a healthy brain. And today we're closer than ever to this modern immortality with cerebroprotection in stroke, as we stay alert with Stroke Alert. Dr. Negar Asdaghi:         This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.  

How Kat gets out of speeding tickets on the show today...and what would you do if you noticed a hidden camera at your VRBO??  Plus we laugh a LOT today - so check it out!!

Is it mum or mam, or maybe mammy? Actress and writer Brona C. Titley chats about accidentally leaving Ireland for a life in London, having a child in the early months of the pandemic and her award-winning career as an actress and comedy writer. Brona and Amy compare stories about the weird things people say to you when you've had a baby and the common misconception that Brona has written all of Robbie Williams' songs!  And, Amy chats to TikTok sensation Serena Terry, better known as Mammy Banter. They look at her success on social media, her life as a mammy, your kids mortifying you in public and her new book. Oh, and there's also a ball shaver…but it's not what you think!